Contact us  HCVets@gmail.com

Follow us on Facebook

One on One Support

Health Concerns
VA Issues  


Information:
Notice: Website under construction,
Contact
HCVets@gmail.com  
 

May 2014 VA Hep C Treatment Guidelines
UPDATE: Feb 26, 2016-
Funding and Prioritization Status Update

UPDATE: March 2016
VA Hep C Treatment Guidelines
VA to treat all vets in system
 

By Judith Graham
VA Extends New Hepatitis C Drugs to All Veterans in Its Health System

 
Orange Count Registry
Vietnam vets blame 'jet guns' for their hepatitis C
By Lily Leung Feb. 14, 2016 
 
CBS News Investigates
Congress outraged over hepatitis C treatment VA can't afford
Dr. Raymond Schinazi played a leading role developing a drug that cures hepatitis C while working seven-eighths of his time for the VA
 
ibtimes.com| By amynordrum
 


Hepatitis C drug costing VA, DoD millions
By Patricia Kime, Staff writer
We're looking at a company who is milking a cash cow for everything it's worth," Sanders said. 
 


VA to outsource care for 180,000 vets with hepatitis C
Dennis Wagner, The Arizona Republic 12:27 a.m. EDT June 21, 2015
 


VA to outsource care for 180,000 vets with hepatitis C
, The Republic | azcentral.com 11:51 a.m. MST June 19, 2015
Dr. David Ross, the VA's director public-health pathogens programs, resigned from the working group. "I cannot in good conscience continue to work on a plan for rationing care to veterans," he wrote.
 


VA Region Stops Referring Patients To Outside Hospitals Thanks To Budget Shortfall
Michael Volpe Contributor ...According to a memo — the entire region has been forced to stop all “non-VA care” referrals due to a budget shortfall.
 

DisabledVeterans.org
OIG INVESTIGATES VA CHOICE PROGRAM PROBLEMS
Sen. Mark Kirk admitted the VA Choice Program is a failed joke in a letter to Secretary Bob McDonald despite attempts to fix it.
 

 
Denied Hep C VA dental care?
Please click here

 
Dried Hepatitis C Blood Exposure 11/23/2013 Weeks later inconspicuous blood transmits virus and more likely to cause accidental exposures to Hep C
 

Lack of Standards for
Mass Vaccinations
1970 Jetgun Nursing Instructions
 

2014 AASLD Study Hepatitis C not an STD

Home
Test the Rest Campaign
Documentation & Surveillance Alerts
Military Hepatitis History  
Understanding The Liver 
VA Flow Sheet for Cirrhosis
VA Defines Risk Factors
 
Hep C & Pro-Prebiotic
Need to know-Grassroots Research
 
Blog Another12Weeks
One Vets' Journey Though Treatment
 

 Ask NOD
 What Would Veterans Do?
Blog for VA Claims
 


Help with VA Claims
 


 
Info: Plan Backfires-
VBA Fast Letter Boost Claims
 
Legal- Fed Regs state:
Judge decision may be relied upon
Cotant v. Principi, 17 Vet.App. 116, 134 (2003),
 
Service Connected Claims
# 1 Conclusion of Law 
# 2 Conclusion of Law 
 
More Claims
Jetgun Decisions
Hep C Decisions
 
Search Board of Appeals Website
BVA Jetgun Decisions
BVA Hepatitis C Decisions

Great Advice!  
After the jetgun win
What to do next

 

 

From Journal of Viral Hepatitis

Management of Chronic Hepatitis C Patients Who have Relapsed or Not Responded to Pegylated Interferon Alfa Plus Ribavirin

D. T. Dieterich; M. Rizzetto; M. P. Manns
12/04/2009; J Viral Hepat. 2009;16(12):833-43. © 2009 Blackwell Publishing

Abstract and Introduction

Abstract

Development of therapeutic strategies for patients with chronic hepatitis C who experience virological breakthrough, relapse or nonresponse lag behind those for treatment-naïve patients. The probability of a previously treated patient responding to re-treatment depends on the nature of the previous regimen, the magnitude of the response to previous treatment and the patient's characteristics. Relapsers have higher sustained virological response rates than nonresponders when re-treated with pegylated interferon plus ribavirin. Re-treatment of nonresponders to pegylated interferon plus ribavirin with the standard 48-week regimen resulted in an approximate 6% sustained response rate in the EPIC-3 program. In the REPEAT trial, the sustained response rate was significantly higher in nonresponders to pegylated interferon alfa-2b (12 kD) plus ribavirin randomized to 72 weeks of peginterferon alfa-2a (40 kD) plus ribavirin, compared with a 48-week regimen (16% vs 8%, P = 0.0006). Based on available data, extended treatment is the best option for these individuals. Undetectable viral RNA at week 12 is an important criterion for re-treatment in the REPEAT and EPIC studies. Maintenance therapy with pegylated interferon is generally ineffective in nonresponders and cannot be recommended. Directly acting antivirals may increase response rates and the burden of adverse events when combined with the standard of care, but will not be available for some years. In conclusion, after careful evaluation of an individual's benefit–risk ratio, a 72-week regimen is the preferred strategy for optimizing sustained response rates in patients who have not responded to the standard of care, provided that viral RNA is undetectable at week 12 of re-treatment.

Introduction

Infection with hepatitis C virus (HCV) often results in chronic hepatitis C, a progressive liver disease that is associated with significant morbidity and mortality. Chronic HCV can lead to liver cirrhosis and hepatocellular carcinoma and is one of the leading indications for liver transplantation worldwide. However, effective treatment is available. The current standard of care for chronic HCV infection is the combination of pegylated interferon plus ribavirin.[1] With this combination, more than 50% of previously untreated patients achieve a sustained virological response (SVR).[2–5]

SVR has been described as 'tantamount to a cure' by the American Gastroenterological Association.[6] Cure of chronic hepatitis C is associated with resolution of symptoms, improvements in health-related quality of life and liver histology and reductions in liver-related morbidity and mortality.[7–14]

Cure rates for chronic hepatitis C have improved significantly with each major evolutionary step in the treatment paradigm for the disease. As the willingness to treat patients and the indications for treatment have expanded, so too have the number of patients in whom HCV has not been eradicated by a first course of treatment. Thus, there is a large and growing pool of 'relapsers' and 'nonresponders' to the standard of care in urgent need of effective treatment.

Much progress has been made in optimizing treatment regimens for patients with chronic hepatitis C.[15,16] However, the development of therapeutic strategies for relapsers and nonresponders lags behind those for treatment-naïve patients. As a result, current treatment guidelines recommend that re-treatment should only be contemplated if the previous course of treatment included conventional (i.e. nonpegylated) interferon.[1] This recommendation is now in need of re-evaluation as recent data have provided insight into how best to re-treat patients with pegylated interferon plus ribavirin.

 

Definition of Relapse and Nonresponse

Relapse and nonresponse are defined on the basis of the virological response to treatment (Fig. 1). A patient is said to have experienced a virological relapse if HCV RNA decreases and remains below the limit of detection (<50 IU/mL) during treatment but becomes detectable after cessation of treatment. If HCV RNA rebounds and becomes detectable in such a patient before treatment is completed, this is referred to as virological breakthrough. Virological nonresponse is evident when the serum HCV RNA level remains above the limit of detection throughout treatment and is formally defined as less than 2 log10 decline in HCV RNA between baseline and week 12. A patient who has less than 1 log10 reduction in serum HCV RNA at week 12 of treatment is said to have had a null response.

 

Figure 1.

Patterns of virological response during and after antiviral treatment. Rapid virological response (RVR, not shown) is defined as undetectable HCV RNA at week 4 of treatment; early virological response (EVR, not shown) is defined as a reduction of ≥2-log10 at week 12; complete EVR (not shown) is defined as undetectable HCV RNA at week 12.

A panel of experts convened by the US Food and Drug Administration recently issued a position statement that included a formal definition of nonresponse for use in future clinical trials (Table 1).[17] In contrast to the situation in clinical trials, in everyday clinical practice, the extent of previous treatment (i.e. dose and duration) and the magnitude of the virological response are often unknown.

 

Which Patients are Most Likely to Relapse or Not Respond to the Standard of Care?

HCV has evolved such that it impairs innate and adaptive host immune mechanisms.[18] However, at present, it is not possible for clinicians to identify nonresponders to treatment with pegylated interferon before treatment is initiated. Certain factors, including infection with HCV genotype 1, high baseline HCV RNA level, African American race, advanced hepatic fibrosis, obesity and insulin resistance, are associated with lower SVR rates, but the presence of one or more of these factors does not preclude a successful treatment outcome. Recent genetic studies have provided insight into the biological basis of nonresponse to interferon-based therapies,[19] and in the future, this may make it possible to differentiate between potential nonresponders and responders to treatment on the basis of gene expression patterns in liver tissue obtained before treatment is initiated.[20–23] In the current standard of care for treatment-naïve patients, on-treatment virological responses at weeks 4 and 12 have evolved as important predictive tools to determine the chance of success. The later a patient clears HCV RNA from the blood, the higher the probability of relapse or nonresponse.